immunotherapy

Overview

Immunotherapy is a broad class of therapeutic approaches that harness, enhance, or redirect the immune system to recognize and control disease. In oncology, it is most commonly used to improve antitumor immune responses by activating T-lymphocytes, modulating dendritic cell function, reducing suppression by regulatory T cell populations, or blocking inhibitory pathways such as CD274 molecule (PD-L1) and cytotoxic T-lymphocyte associated protein 4. More recently, immunotherapy has also been discussed in the context of immune-mediated neurologic disease and inflammatory conditions, reflecting its wider medical relevance beyond cancer.

Biologically, immunotherapy acts by shifting the balance between immune activation and immune evasion. Its effects are strongly influenced by the tumor microenvironment, including macrophage polarization, proinflammatory cytokine signaling, and the presence of immune checkpoints. In solid tumors, response can be shaped by tumor-intrinsic factors, immune infiltration, and interactions with the gut microbiome or human gut flora. Because of this complexity, immunotherapy is often studied in combination with radiotherapy, chemotherapy, Targeted therapies, or biologic agents such as pembrolizumab and durvalumab.

Recent Publications Summary (latest 30 papers)

Recent publications on immunotherapy in cancer focused largely on its integration into multimodal treatment strategies and on the biological context that may influence response. In cisplatin-resistant small cell lung cancer, a review highlighted immunotherapy as one of several emerging approaches being explored to overcome resistance, alongside targeted therapy and novel chemotherapeutic agents 41869709Mar. In lung cancer more broadly, exosome-mediated signaling within the tumor microenvironment was described as a contributor to immune evasion and resistance to immunotherapy, with tumor-derived exosomes impairing cytotoxic T lymphocyte function, promoting regulatory T cells, and supporting an M2 macrophage phenotype 41759799Feb.

In genitourinary malignancies, neoadjuvant systemic therapy studies emphasized the expanding role of immune checkpoint inhibitors. For bladder cancer, neoadjuvant cisplatin-based chemotherapy with or without immunotherapy was described as standard of care, and pathologic complete response was discussed as a validated surrogate after chemotherapy and a promising surrogate for immunotherapy-based neoadjuvant treatment 41774881Mar. The same review noted that enfortumab vedotin and immune checkpoint inhibitor combinations have broadened treatment options, with ongoing studies evaluating postoperative strategies guided by circulating tumor DNA 41774881Mar.

In renal cell carcinoma, the evidence base for neoadjuvant immunotherapy remains early, with no approved neoadjuvant regimens and treatment outside clinical trials not recommended 41774881Mar. However, early immune checkpoint inhibitor-based combinations were reported to be feasible and safe, and capable of inducing pathologic responses including pathologic complete response 41774881Mar.

Beyond direct treatment studies, recent work also addressed enabling platforms and access issues relevant to immunotherapy. lung cancer organoids were presented as a precision medicine model for studying immunotherapy applications in a setting that better preserves tumor heterogeneity and microenvironmental features than conventional cell lines 41676863Feb. Separately, an early-stage oncology policy review noted that immunotherapy has become one of the effective newer treatments in early-stage Cancers, while also highlighting persistent barriers to reimbursement and access when mature overall survival data are not yet available 41653456Feb.

What Changes, What Holds

1. Immunotherapy is being positioned as a strategy to overcome resistance and microenvironmental immune escape, not just as a direct immune activator
NEW DIRECTION Exosome-driven suppression of cytotoxic T cells, expansion of regulatory T cells, and support for an M2 macrophage state add a resistance biology that the Overview does not spell out, even though it already notes tumor microenvironment effects. The practical implication is that response may depend on blocking intercellular communication as much as on checkpoint blockade itself 41759799Feb.

2. Neoadjuvant immunotherapy is moving from experimental add-on toward a validated component of bladder cancer treatment planning
REINFORCES The new work sharpens the Overview’s point that immunotherapy is often combined with chemotherapy and other biologics by showing that checkpoint-based perioperative strategies are now part of standard-of-care discussions in bladder cancer, with response metrics being used to guide postoperative decisions 41774881Mar. It does not overturn the baseline; it extends the established multimodal role into a more specific clinical setting.

3. Early renal cell carcinoma data support feasibility, but not routine neoadjuvant use outside trials
REINFORCES This keeps the baseline intact by showing that checkpoint inhibitor combinations can produce pathologic responses, while also underscoring that the evidence remains too immature for approved neoadjuvant regimens 41774881Mar. The main consequence is caution: immunotherapy’s expanding role in solid tumors does not yet justify routine preoperative use in this disease.

4. Immunotherapy research is increasingly being shaped by organoid models and access constraints, which affect how the field is studied and adopted
METHOD lung cancer organoids add a more faithful experimental platform for testing immunotherapy than conventional cell lines, changing the study system rather than the therapeutic concept itself 41676863Feb. The policy review adds a separate implementation issue: newer immunotherapies may be effective earlier in cancer care, but reimbursement and access remain limited when mature overall survival data are lacking 41653456Feb.

Overview update candidates: exosome-mediated immune evasion and resistance mechanisms in lung cancer; perioperative checkpoint inhibitor use in bladder cancer and ctDNA-guided postoperative strategies; organoid-based modeling and access/reimbursement barriers for early-stage immunotherapy.